Parathyroid Disorders Market, By Type (Drug Class, and Diagnostic Method), By Disorder Type (Primary Hyperparathyroidism, Secondary Hyperparathyroidism, Tertiary Hyperparathyroidism, and Hypoparathyroidism), By Route of Administration (Oral and Parenteral

The Global Parathyroid Disorders Market is estimated to be valued at USD 11.10 billion in 2025 and is expected to reach USD 13.93 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.3% from 2025 to 2032. The global parathyroid disorders market has witnessed significant growth in recent years, driven by the increasing prevalence of parathyroid disorders, advancements in diagnostic techniques, and the development of novel treatment options. Parathyroid disorders, which include hyperparathyroidism and hypoparathyroidism, are characterized by abnormal functioning of the parathyroid glands, leading to imbalances in calcium and phosphate levels in the body. These disorders can have severe consequences on bone health, cardiovascular function, and overall quality of life. With the rising awareness about parathyroid disorders and the availability of advanced treatment modalities, the global parathyroid disorders market is expected to experience substantial growth during the forecast period.

Market Dynamics:

The global parathyroid disorders market is driven by several factors, including the increasing prevalence of parathyroid disorders, particularly primary hyperparathyroidism, which is more common in postmenopausal women. Additionally, the growing geriatric population, which is more susceptible to parathyroid disorders, is expected to fuel market growth. Advancements in diagnostic techniques, such as improved imaging modalities and genetic testing, have enabled early detection and accurate diagnosis of parathyroid disorders, further driving market growth. Moreover, the development of novel treatment options, including targeted therapies and minimally invasive surgical procedures, has expanded the treatment landscape and improved patient outcomes. However, the market growth may be restrained by factors such as the high cost of treatments, limited awareness about parathyroid disorders in certain regions, and the potential side effects associated with some treatment options. Despite these restraints, the market presents significant opportunities for growth, driven by the increasing focus on research and development activities, collaborations between industry players and academic institutions, and the emergence of personalized medicine approaches in the field of parathyroid disorders.

Key Features of the Study:

• This report provides in-depth analysis of the global parathyroid disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global parathyroid disorders market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bristol-Myers Squibb Company, AbbVie Inc., Regeneron Pharmaceuticals, Inc., Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Sandoz (a Novartis division), and Otsuka Pharmaceutical Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global parathyroid disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global parathyroid disorders market

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
• Drug Class
• Parathyroid Hormone (PTH) Analogues
• Bisphosphonates
• Calcimimetics
• Vitamin D Analogues
• Phosphate Binders
• Diagnostic Method
• Blood Tests
• Imaging Techniques
• Urine Tests
• Disorder Type Insights (Revenue, USD Bn, 2020 - 2032)
• Primary Hyperparathyroidism
• Secondary Hyperparathyroidism
• Tertiary Hyperparathyroidism
• Hypoparathyroidism
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
• Oral
• Parenteral
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
• Pediatric
• Adult
• Geriatric
• Gender Insights (Revenue, USD Bn, 2020 - 2032)
• Male
• Female
• End User Insights (Revenue, USD Bn, 2020 - 2032)
• Hospitals
• Specialty Clinics
• Outpatient Centers
• Research Institutes
• Diagnostic Centers
• Home Healthcare
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa
• Key Players Insights
• Amgen Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AbbVie Inc.
• Regeneron Pharmaceuticals, Inc.
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• Sandoz (a Novartis division)
• Otsuka Pharmaceutical Co., Ltd.

Show more